item 1a.   risk factors the statements in this section describe the major risks to our business and should be considered carefully. in addition, these statements constitute our cautionary statements under the private securities litigation reform act of 1995.
our disclosure and analysis in this 2019 form 10-k and in our 2019 annual report to shareholders contain forward-looking statements. from time to time, we also provide forward-looking statements in other materials we release to the public, as well as oral forward-looking statements. such forward-looking statements involve substantial risks and uncertainties. we have tried, wherever possible, to identify such statements by using words such as "will," "may," "could," "likely," "ongoing," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "assume," "target," "forecast," "guidance," "goal," "objective," "aim," "seek" and other words and terms of similar meaning or by using future dates in connection with any discussion of, among other things, our anticipated operating and financial performance, business plans and prospects, expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, revenue contribution, growth, performance, timing of exclusivity and potential benefits, strategic reviews, capital allocation objectives, plans for and prospects of our acquisitions and other business-development activities, benefits anticipated from the reorganization of our commercial operations in 2019, sales efforts, expenses, interest rates, foreign exchange rates, the outcome of contingencies, such as legal proceedings, government regulation, our ability to successfully capitalize on growth opportunities or prospects, manufacturing and product supply and plans relating to share repurchases and dividends. in particular, these include statements relating to future actions, including, among others, the expected timing, benefits, charges and/or costs in connection with our agreement to combine upjohn with mylan to create a new global pharmaceutical company, viatris, set forth in the item 1. business--about pfizer and item 1a. risk factors--pending combination of upjohn with mylan sections in this 2019 form 10-k and the overview of our performance, operating environment, strategy and outlook--our business development initiatives and --our strategy sections and the notes to consolidated financial statements-note 1a. basis of presentation and significant accounting policies--basis of presentation in our 2019 financial report; the expected impact of patent expiries on our business set forth in the item 1. business--patents and other intellectual property rights section in this 2019 form 10-k and in the overview of our performance, operating environment, strategy and outlook--our operating environment--industry-specific challenges--intellectual property rights and collaboration/licensing rights section in our 2019 financial report; the expected competition from certain generic manufacturers in china in the item 1. business--competition--generic products and item 1a. risk factors--generic competition sections in this 2019 form 10-k; the anticipated costs related to our preparations for brexit set forth in the item 1. business--government regulation and price constraints--outside the united states--brexit section in this 2019 form 10-k and the overview of our performance, operating environment, strategy and outlook--the global economic environment section in our 2019 financial report; the availability of raw materials for 2020 set forth in item 1. business--raw materials in this 2019 form 10-k; the expected pricing pressures on our products in the u.s. and internationally and the anticipated impact to our business set forth in the item 1. business--government regulation and price constraints and item 1a. risk factors--pricing and reimbursement sections in this 2019 form 10-k; the anticipated impact of climate change on pfizer set forth in item 1. business--environmental matters in this 2019 form 10-k; the expected demerger of the gsk consumer healthcare joint venture set forth in the item 1a. risk factors--consumer healthcare joint venture with gsk section in this 2019 form 10-k; the benefits expected from the reorganization of our commercial operations in 2019 and our expectations regarding growth set forth in the overview of our performance, operating environment, strategy and outlook--our strategy--organizing for growth section in our 2019 financial report; our anticipated liquidity position set forth in the overview of our performance, operating environment, strategy and outlook-the global economic environment and the analysis of financial condition, liquidity and capital resources sections in our 2019 financial report; the anticipated costs and savings from certain of our initiatives, including transforming to a more focused company initiative, set forth in the overview of our performance, operating environment, strategy and outlook-transforming to a more focused company and costs and expenses-restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives sections and the notes to consolidated financial statements-note 3. restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives in our 2019 financial report; our plans for increasing investment in the u.s. set forth in the overview of our performance, operating environment, strategy and outlook--our strategy--capital allocation and expense management--increasing investment in the u.s. section in our 2019 financial report; the financial guidance set forth in the overview of our performance, operating environment, strategy and outlook-our financial guidance for 2020 section in our 2019 financial report; the expected impact of the advisory committee on immunization practices recommendation for prevnar 13 for adults 65 and older on prevnar 13's revenues set forth in the analysis of the consolidated statements of income--revenues--selected product discussion--prevnar 13/prevenar 13 (biopharma) section in our 2019 financial report; the expected impact of updates to the prescribing information for xeljanz on its growth set forth in the analysis of the consolidated statements of income--revenues--selected product discussion--xeljanz (biopharma) section in our 2019 financial report; the benefits expected from our business development transactions; the planned capital spending set forth in the analysis of financial condition, liquidity and capital resources-selected measures of liquidity and capital resources-contractual obligations section in our 2019 financial report; the expected payments to our unfunded u.s. supplemental (non-qualified) pension plans, postretirement plans and deferred compensation plans and expected funding obligations set forth in the analysis of financial condition, liquidity and capital resources-selected measures of liquidity and capital resources-contractual obligations section; and the voluntary contribution we expect to make during 2020 for the u.s. qualified plans set forth in the notes to consolidated financial statements-note 11. pension and postretirement benefit plans and defined contribution plans in our 2019 financial report.
pfizer inc.   2019 form 10-k table of contents we cannot guarantee that any forward-looking statement will be realized. achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. you should bear this in mind as you consider forward-looking statements, and you are cautioned not to put undue reliance on forward-looking statements.
we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the sec. you are advised, however, to consult any further disclosures we make on related subjects. also note that we provide the following cautionary discussion of risks, uncertainties and possibly inaccurate assumptions relevant to our businesses. these are factors that, individually or in the aggregate, may cause our actual results to differ materially from expected, projected or historical results. we note these factors for investors as permitted by the private securities litigation reform act of 1995. you should understand that it is not possible to predict or identify all such factors. consequently, you should not consider the following to be a complete discussion of all potential risks or uncertainties.
risks related to our business, industry and operations:
managed care trends private third-party payers, such as health plans, and other managed care entities, such as pbms, continue to take action to manage the utilization of drugs and control the cost of drugs. consolidation among mcos has increased the negotiating power of mcos and other private third-party payers. private third-party payers, as well as governments, increasingly employ formularies to control costs by taking into account discounts in connection with decisions about formulary inclusion or favorable formulary placement. failure to obtain or maintain timely or adequate pricing or favorable formulary placement for our products, or failure to obtain such formulary placement at favorable pricing, could adversely impact revenue. private third-party payers often implement formularies with copayment tiers to encourage utilization of certain drugs and have also been raising co-payments required from beneficiaries, particularly for branded pharmaceuticals and biotechnology products. private third-party payers are also implementing new initiatives like so-called "copay accumulators" (policies that provide that the value of copay assistance does not count as out-of-pocket costs that are applied toward deductibles) that can shift more of the cost burden to manufacturers and patients. this cost shifting has increased consumer interest and input in medication choices, as they pay for a larger portion of their prescription costs and may cause consumers to favor lower cost generic alternatives to branded pharmaceuticals. third-party payers also use additional measures such as new-to-market blocks, exclusion lists, indication-based pricing, and value-based pricing/contracting to improve their cost containment efforts, and are also increasingly imposing utilization management tools, such as clinical protocols, requiring prior authorization for a branded product if a generic product is available or requiring the patient to first fail on one or more generic products before permitting access to a branded medicine. as the u.s. private third-party payer market consolidates further and as more drugs become available in generic form, biopharmaceutical companies may face greater pricing pressure from private third-party payers, who will continue to drive more of their patients to use lower cost generic alternatives.
generic competition competition from manufacturers of generic drugs is a major challenge for our branded products around the world, and the loss or expiration of intellectual property rights can have a significant adverse effect on our revenues. in addition, our patented products may face generic competition before patent exclusivity expires, including upon the "at-risk" launch (despite pending patent infringement litigation against the generic product) by a manufacturer of a generic version of one of our patented products. generic competition could lead to our loss of a major portion of revenues for that product in a very short period of time. a number of our products have experienced significant generic competition over the last few years. for example, lyrica (a product in our upjohn business) lost patent protection in the u.s. in june 2019 and multi-source generic competition began in july 2019. also, the basic product patent for chantix in the u.s. will expire in november 2020. in china, we are expected to face further intensified competition by certain generic manufacturers, which may result in price cuts and volume loss of some of our products.
also, generic manufacturers have filed applications with the fda seeking approval of product candidates that such companies claim do not infringe our patents or that our patents are not valid; these include candidates that would compete with, among other products, eliquis, ibrance and xeljanz. our licensing and collaboration partners also face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights. in addition, our patent-protected products may face competition in the form of generic versions of competitors' branded products that lose their market exclusivity.
pfizer inc.   2019 form 10-k table of contents competitive products we cannot predict with accuracy the timing or impact of the introduction of competitive products, including new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat diseases and conditions similar to those treated by our in-line drugs and drug candidates. the introduction of competitive products can result in erosion of the sales of our existing products and potential sales of products in development, as well as unanticipated product obsolescence. competitive product launches have occurred in recent years, and certain potentially competitive products are in various stages of development. some of these have been filed for approval with the fda and with regulatory authorities in other countries.
we also produce generic and biosimilar pharmaceutical products that compete with products from competitors, including other generic and biosimilar manufacturers. the ability to launch a generic or biosimilar pharmaceutical product at or before the anticipated formation of the generic or biosimilar marketplace is important to that product's profitability. with increasing competition in the generic or biosimilar product markets, our success will depend on our ability to bring new products to market quickly. the fda, along with other regulatory agencies around the world, has been experiencing a backlog of generic drug applications, which may result in delayed approvals of new generic products over the next few years. also, we may face access challenges for our biosimilar products where our product may not receive appropriate coverage/reimbursement access or remains in a disadvantaged position relative to the innovator product. for example, inflectra has experienced access challenges among commercial payers. in september 2017, pfizer filed suit in the u.s. district court for the eastern district of pennsylvania against johnson & johnson (j&j) alleging that j&j's exclusionary contracts and other anticompetitive practices concerning remicadeÂ® (infliximab) violate federal antitrust laws.
dependence on key in-line products we recorded direct product and/or alliance revenues of more than $1 billion for each of eight biopharmaceutical products in 2019: prevnar 13/prevenar 13, ibrance, eliquis, lyrica, xeljanz, lipitor, enbrel and chantix/champix. those products accounted for 49% of our total revenues in 2019. if these products or any of our other major products were to become subject to problems such as loss of patent protection (if applicable), changes in prescription growth rates, material product liability litigation, unexpected side effects, regulatory proceedings, publicity affecting doctor or patient confidence, pressure from existing competitive products, changes in labeling, pricing and access pressures, supply shortages or, if a new, more effective treatment should be introduced, the adverse impact on our revenues could be significant. a number of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and patents covering a number of our best-selling medicines are, or have been, the subject of pending legal challenges. for example, as a result of a patent litigation settlement, teva pharmaceuticals usa, inc. launched a generic version of viagra (a product in our upjohn business) in the u.s. in december 2017. in addition, lyrica (a product in our upjohn business) lost patent protection in the u.s. in june 2019 and multi-source generic competition began in july 2019. also, the basic product patent for chantix in the u.s. will expire in november 2020. in addition, our revenues could be significantly impacted by the timing and rate of commercial acceptance of key new products. for additional information, see the item 1. business--patents and other intellectual property rights section in this 2019 form 10-k. further, our alliance revenues will be adversely affected by the termination or expiration of collaboration and co-promotion agreements that we have entered into and that we may enter into from time to time.
research and development investment the discovery and development of safe, effective new products, as well as the development of additional uses for existing products, are necessary for the continued strength of our businesses. our product lines must be replenished over time in order to offset revenue losses when products lose their market exclusivity, as well as to provide for earnings growth. our growth potential depends in large part on our ability to identify and develop new products or new indications for existing products that address unmet medical needs and receive reimbursement from payers, either through internal r&d or through collaborations, acquisitions, joint ventures or licensing or other arrangements with third parties. however, balancing current growth, investment for future growth and the delivery of shareholder return remains a major challenge. the average costs of product development continue to rise, as do the regulatory requirements in many therapeutic areas, which may affect the number of candidates funded as well as the sustainability of the r&d portfolio. our ongoing investments in new product introductions and in r&d for new products and existing product extensions could exceed corresponding sales growth.
additionally, our r&d investment plans and resources may not be correctly matched between science and markets, and failure to invest in the right technology platforms, therapeutic segments, product classes, geographic markets and/or in-licensing and out-licensing opportunities could adversely impact the productivity of our pipeline. further, even if the areas with the greatest market attractiveness are identified, the scientific approach may not succeed for any given program despite the significant investment required for r&d, and the commercial potential of the product may not be as competitive as expected because of the highly dynamic market environment and the hurdles in terms of access and reimbursement.
we continue to strengthen our global r&d organization and pursue strategies intended to improve innovation and overall productivity in r&d to achieve a sustainable pipeline that is positioned to deliver value in the near-term and over time. these strategies may not deliver the desired result, which could affect growth and profitability in the future.
pfizer inc.   2019 form 10-k table of contents biosimilars abbreviated legal pathways for the approval of biosimilars exist in many international markets and, since the passage of the aca, a framework for such approval exists in the u.s. if competitors are able to obtain marketing approval for biosimilars referencing our biologic products, our biologic products may become subject to competition from these biosimilars, with attendant competitive pressure, and price reductions could follow. for example, enbrel faces ongoing biosimilar competition in most european markets. the loss of patent rights, due to patent expiration or litigation, could trigger competition.
we are developing and commercializing biosimilar medicines. risks related to our commercialization of biosimilars include the potential for steeper than anticipated price erosion due to increased competitive intensity, coupled with intellectual property challenges that may preclude timely commercialization of our potential biosimilar products. there is also a risk of lower uptake for biosimilars due to various factors that may vary for different biosimilars (e.g., anti-competitive practices, physician reluctance to prescribe biosimilars for existing patients taking the originator product, or misaligned financial incentives). see also the competitive products risk factor above.
research studies decisions about research studies made early in the development process of a drug or vaccine candidate can have a substantial impact on the marketing strategy and payer reimbursement possibilities if it receives regulatory approval. for example, a wider range of studies can lead to approval for a broader set of indications that may impact the marketing and payer reimbursement process. however, each additional indication and its reimbursement potential must be balanced against the time and resources required to demonstrate benefit, the increased complexity of development and manufacturing and the potential delays to approval of the lead indication. we try to plan clinical trials prudently and to reasonably anticipate and address challenges, but there is no guarantee that an optimal balance between trial conduct, speed and desired outcome will be achieved each time. the degree to which such potential challenges are foreseen and adequately addressed could affect our future results.
international operations our international operations could be affected by currency fluctuations, capital and exchange controls, economic conditions, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, trade regulations and procedures and actions affecting approval, production, pricing, and marketing of, reimbursement for and access to our products, as well as by political unrest, unstable governments and legal systems and inter-governmental disputes. any of these changes could adversely affect our business.
many emerging markets have experienced growth rates in excess of developed markets, leading to an increased contribution to the industry's global performance. as a result, we have been employing strategies to grow in emerging markets. however, our strategies in emerging markets may not be successful and these countries may not continue to sustain these growth rates. for example, even though china is growing faster than most emerging markets, we face certain challenges in china due to government imposed pricing controls affecting certain pfizer medicines. in addition, some emerging market countries may be particularly vulnerable to periods of financial or political instability or significant currency fluctuations or may have limited resources for healthcare spending. even though we constantly monitor the evolving emerging markets for any unanticipated risk to pfizer, certain financial or political events in such markets can adversely affect our results.
specialty pharmaceuticals specialty pharmaceuticals are medicines that treat rare or life-threatening conditions that typically have smaller patient populations. the growing availability and use of innovative specialty pharmaceuticals, combined with their relative higher cost as compared to other types of pharmaceutical products, has generated payer interest in developing cost-containment strategies targeted to this sector. the impact of payers' efforts to control access to and pricing of specialty pharmaceuticals is increasing. a number of factors create a more challenging paradigm for pfizer given our growing specialty business portfolio such as formulary restrictions and increasing use of utilization management tools such as step edits, which can lead to higher negotiated rebates or discounts to health plans and pbms in the u.s., as well as the increasing use of health technology assessments and government pressures in markets around the world.
product manufacturing, sales and marketing risks difficulties or delays in product manufacturing, sales or marketing could affect future results through regulatory actions, shut-downs, work stoppages or strikes, approval delays, withdrawals, recalls, penalties, supply disruptions, shortages or stock-outs, reputational harm, product liability or unanticipated costs. examples of such difficulties or delays include, but are not limited to, the inability to increase production capacity commensurate with demand; the failure to predict market demand for, or to gain market acceptance of, approved products; the possibility that the supply of component materials is delayed or unavailable and that the quality of such materials are substandard and not detected; the possibility that we may fail to maintain appropriate quality standards throughout our internal and external supply network and/or comply with cgmps and other applicable regulations such as serialization (which allows for track and trace of products in the supply chain to enhance patient safety);
pfizer inc.   2019 form 10-k table of contents risks to supply chain continuity and commercial operations as a result of natural (including hurricanes, earthquakes and floods) or man-made disasters (including arson or terrorist attacks) at our facilities or at a supplier or vendor, including those that may be related to climate change; failure to maintain the integrity of our supply chains against economic adulteration, product diversion, product theft, counterfeit goods and cyberattacks. as an example, we have been experiencing production issues with genotropin that will decrease revenue from that product.
regulatory agencies periodically inspect our drug manufacturing facilities to evaluate compliance with cgmp or other applicable requirements. failure to comply with these requirements may subject us to possible legal or regulatory actions, such as warning letters, suspension of manufacturing, seizure of product, injunctions, debarment, recall of a product, delays or denials of product approvals, import bans or denials of import certifications, any of which could have a material adverse effect on our business, financial condition and results of operations. in february 2017, for example, we received a warning letter from the fda communicating the fda's view that certain violations of cgmp regulations exist at hospira's manufacturing facility in mcpherson, kansas. we undertook corrective actions to address the concerns raised by the fda. in january 2018, the fda upgraded the status of pfizer's mcpherson manufacturing facility to vai based on an october 2017 inspection. the change to vai status lifted the compliance hold that the fda placed on approval of pending applications. in june 2018, the fda informed us that it had completed an evaluation of corrective actions and closed out the february 2017 warning letter issued to our mcpherson manufacturing facility after determining that we had addressed the violations contained in the warning letter. in july-august 2018, the fda conducted a follow-up inspection of our mcpherson facility and issued an inspection report noting several findings. pfizer responded to the fda's findings, and is in the process of implementing a corrective and preventive action plan to address the fda's concerns. on the basis of the july-august 2018 fda inspection, the fda changed the inspection classification of the mcpherson site to official action indicated (oai). future fda inspections and regulatory activities will further assess the adequacy and sustainability of these corrections implemented at the site. communication with the fda on the status of the mcpherson site is ongoing. as a result of the current oai classification, the fda may refuse to grant premarket approval of applications and/or the fda may refuse to grant export certificates related to products manufactured at our mcpherson site until the site status is upgraded, which upgrade would be based on a re-inspection by the fda. we have been experiencing shortages of products from the legacy hospira portfolio, among others, largely driven by capacity constraints, technical issues, supplier quality concerns or unanticipated increases in demand. we have made considerable progress in remediating issues at legacy hospira facilities manufacturing sterile injectables and have substantially improved supply from most of these sites. continuing product shortage interruption at these manufacturing facilities could negatively impact our financial results.
in addition, in september 2017, meridian medical technologies, inc., a subsidiary of pfizer inc., received a warning letter from the fda asserting the fda's view that certain violations of cgmp and quality system regulations exist at meridian's manufacturing sites in st. louis, missouri and classifying the site as oai. meridian responded to the warning letter and committed to making improvements across the sites. we have made considerable progress addressing the concerns raised by the fda, and communication with the fda is ongoing. future fda inspections and regulatory activities will further assess the adequacy and sustainability of these corrections implemented at the site. as a result of the oai classification, the fda may refuse to grant premarket approval of applications and/or the fda may refuse to grant export certificates related to products manufactured at our st. louis sites.
collaborations and other relationships with third parties we depend on third-party collaborators, service providers, and others in the research, development, manufacturing and commercialization of our products and product candidates and also enter into joint ventures and other business development transactions in connection with our business. to achieve expected longer term benefits, we may make substantial upfront payments in such transactions, which may negatively impact our reported earnings. we rely heavily on these parties for multiple aspects of our drug development, manufacturing and commercialization activities, but we do not control many aspects of those activities. we also outsource certain services to other parties, including transaction processing, accounting, information technology, manufacturing, clinical trial recruitment and execution, clinical lab services, non-clinical research, safety services, integrated facilities management and other areas. failure by one or more of these third parties to complete activities on schedule or in accordance with our expectations; failure by one or more of these parties to meet their contractual or other obligations to pfizer; failure of one or more of these parties to comply with applicable laws or regulations; or any disruption in the relationships between pfizer and one or more of these third parties, could delay or prevent the development, approval, manufacturing or commercialization of our products and product candidates, could expose us to suboptimal quality of service delivery or deliverables, could result in repercussions such as missed deadlines or other timeliness issues, erroneous data and supply disruptions, and could also result in non-compliance with legal or regulatory requirements or industry standards or reputational harm, all with potential negative implications for our product pipeline and business.
biopharmaceutical wholesalers in 2019, our largest biopharmaceutical wholesaler accounted for approximately 16% of our total revenues (and approximately 32% of our total u.s. revenues), and our top three biopharmaceutical wholesalers accounted for approximately 37% of our total revenues (and approximately 79% of our total u.s. revenues). if one of our significant biopharmaceutical wholesalers should encounter financial or other difficulties, such wholesaler might decrease the amount of business that it does with us, and we might be unable to collect all the amounts that the wholesaler owes us on a timely basis or at all, which could negatively impact pfizer inc.   2019 form 10-k table of contents our results of operations. in addition, we expect that consolidation and integration of pharmacy chains and wholesalers will increase competitive and pricing pressures on pharmaceutical manufacturers, including us.
business development activities we expect to continue to enhance our in-line products and product pipeline through various forms of business development, which can include alliances, licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions, divestments, mergers and acquisitions. however, these enhancement plans are subject to the availability and cost of appropriate opportunities, competition from other pharmaceutical companies that are seeking similar opportunities and our ability to successfully identify, structure and execute transactions, including the ability to satisfy the conditions to closing of announced transactions in the anticipated timeframes or at all, and successfully integrate acquisitions. pursuing these opportunities may require us to obtain additional equity or debt financing, and could result in increased leverage and/or a downgrade of our credit ratings. where we acquire debt or equity securities as all or part of the consideration for business development activities, such as in connection with our contribution agreement entered into with allogene therapeutics, inc., the value of those securities will fluctuate, and may depreciate in value. we may not control the company in which we acquire securities, such as in connection with a divestiture or collaborative arrangement, and as a result, we will have limited ability to determine its management, operational decisions and policies. further, while we seek to mitigate risks and liabilities of such transactions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. legal proceedings or regulatory issues often arise as a result of activities that occurred at acquired companies, their partners and other third parties. in 2016, for example, we paid $784.6 million to resolve allegations related to wyeth's reporting of prices to the government with respect to protonix for activities that occurred prior to our acquisition of wyeth. for these and other reasons, we may not realize the anticipated benefits of such transactions, and expected synergies and accretion may not be realized within the expected timeframes, or at all.
counterfeit products a counterfeit medicine is one that has been deliberately and fraudulently mislabeled as to its identity and source. a counterfeit pfizer medicine, therefore, is one manufactured by someone other than pfizer, but which appears to be the same as an authentic pfizer medicine. the prevalence of counterfeit medicines is a significant and growing industry-wide issue due to a variety of factors, including, but not limited to, the following: the widespread use of the internet, which has greatly facilitated the ease by which counterfeit medicines can be advertised, purchased and delivered to individual patients; the availability of sophisticated technology that makes it easier for counterfeiters to make counterfeit medicines; the growing involvement in the medicine supply chain of under-regulated wholesalers and repackagers; the lack of adequate inspection at certain international postal facilities as counterfeit medicines are increasingly delivered direct to customers in small parcel packages; the tendency to misuse and abuse medicines; and the relatively modest risk of penalties faced by counterfeiters compared to the large profits that can be earned by them from the sale of counterfeit medicines. further, laws against pharmaceutical counterfeiting vary greatly from country to country, and the enforcement of existing law varies greatly from jurisdiction to jurisdiction. for example, in some countries, pharmaceutical counterfeiting is not a crime; in others, it may result in only minimal sanctions. in addition, those involved in the distribution of counterfeit medicines use complex transport routes in order to evade customs controls by disguising the true source of their products.
pfizer's global reputation makes its medicines prime targets for counterfeiting organizations. counterfeit medicines continue to pose a significant risk to patient health and safety because of the conditions under which they are manufactured-often in unregulated, unlicensed, uninspected and unsanitary sites-as well as the lack of regulation of their contents. counterfeiters have been recently evolving to counterfeit life sustaining medications such as oncology medicines. this shift significantly increases the risk to patients who, for instance, unsuspectingly purchase counterfeit oncology medications from illicit online "pharmacies" operated by criminal counterfeiting organizations. failure to mitigate this new threat posed by counterfeit biopharma medicines could adversely impact our business, by, among other things, causing the loss of patient confidence in the pfizer name and in the integrity of our medicines, potentially resulting in lost sales, product recalls, and an increased threat of litigation.
we have an enterprise-wide strategy to counteract the threats associated with counterfeit medicines, and focused on educating patients and health care providers to reduce demand through awareness; increasing engagement and education of global law enforcement, customs and regulatory agencies about the growing prevalence of counterfeit life sustaining medicines; enhancing online identification and disruption efforts in partnership with pharmaceutical associations to optimize resources and impact; educating legislators about the risk to the security of the international drug supply chain by illicit manufacturing and distribution networks operated by transnational criminal organizations; supporting efforts by law enforcement authorities to prosecute counterfeiters; assessing new and existing technologies to seek to make it more difficult for counterfeiters to copy our products and easier for patients and healthcare providers to distinguish authentic from counterfeit medicines; and using data analytics and risk assessment tools to better target the factors that give rise to the counterfeiting problem in the first place. however, our efforts and the efforts of others may not be entirely successful, and the presence of counterfeit medicines may continue to increase.
pfizer inc.   2019 form 10-k table of contents risks related to government regulation and legal proceedings:
pricing and reimbursement u.s. and international governmental regulations that mandate price controls and limitations on patient access to our products or establish prices paid by government entities or programs for our products impact our business, and our future results could be adversely affected by changes in such regulations or policies.
in the u.s., many of our products are subject to increasing pricing pressures. pharmaceutical product pricing is subject to enhanced government and public scrutiny and calls for reform. some states have implemented, and other states are considering, pharmaceutical price controls or patient access constraints under the medicaid program, and some states are considering price-control regimes that would apply to broader segments of their populations that are not medicaid-eligible. there have also been recent state legislative efforts to address drug costs, which generally have focused on increasing transparency around drug costs or limiting drug prices. efforts by government officials or legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation on drug importation, could adversely affect our business if implemented. see the discussion regarding pricing and reimbursement in the item 1. business-government regulation and price constraints-in the united states-pricing and reimbursement section in this 2019 form 10-k.
we encounter similar regulatory and legislative issues in most other countries. in certain international markets, such as the different eu member states, the u.k., china, japan, canada and south korea, governments have significant power as large single payers to regulate prices, access criteria (e.g., through public or private health technology assessments), or other means of cost control, particularly under recent global financing pressures. as a result, we expect that pressures on the pricing component of operating results will continue. for example, china, in 2013, began to implement a qce process, under which numerous local generics have officially been deemed bioequivalents of a qualified reference drug. china's government subsequently initiated a pilot project for centralized vbp in 2018, which included 25 molecules of drugs and covered 11 major chinese cities. under this procurement model, a tender process was established whereby a certain portion of included molecule volumes were guaranteed to tender winners. this tender process was intended to contain healthcare costs by driving utilization of generics and bioequivalents that had passed qce, and has resulted in dramatic price cuts for off-patent medicines. china's government began nationwide expansion of the vbp pilot in december 2019. see the discussion regarding these government initiatives in china in the item 1. business-government regulation and price constraints-outside the united states-china pricing pressures section in this 2019 form 10-k. we anticipate that these initiatives will continue to increase pricing pressures on our drug products in china in the future.
the adoption of restrictive price controls in new jurisdictions or more restrictive ones in existing jurisdictions or the failure to obtain or maintain timely or adequate pricing could also adversely impact revenue. in our vaccines business, we participate in a tender process in many countries for participation in national immunization programs. failure to secure participation in national immunization programs or to obtain acceptable pricing in the tender process could adversely affect our business.
u.s. healthcare reform the u.s. healthcare industry is highly regulated and subject to frequent and substantial changes. for example, the aca was enacted by congress in march 2010 and established a major expansion of healthcare coverage, financed in part by a number of new rebates, discounts, and taxes that had a significant effect on our expenses and profitability. see the discussion in the item 1. business-government regulation and price constraints-in the united states section in this 2019 form 10-k. we face uncertainties due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the aca. there is additional uncertainty given the ruling in december 2019 by the u.s. circuit court of appeals for the fifth circuit in texas v. azar that the individual mandate, which is a significant provision of the aca, is unconstitutional. the case has been remanded to a lower court to determine whether the individual mandate is inseparable from the entire aca, in which case the aca as a whole would be rendered unconstitutional. in the meantime, the remaining provisions of the law remain in effect. the revenues generated for pfizer by the health insurance exchanges and medicaid expansion under the aca are not material, so the impact of full invalidation of the law is expected to be limited. however, any future replacement of the aca may adversely affect our business and financial results, particularly if the legislation reduces incentives for employer-sponsored insurance coverage or dramatically increases industry taxes and fees. any future healthcare reform efforts may adversely affect our business and financial results.
other u.s. federal or state legislative or regulatory action and/or policy efforts could adversely affect our business, including, among others, general budget control actions, changes in patent laws, the importation of prescription drugs from outside the u.s. at prices that are regulated by governments of various foreign countries (which is among the u.s. presidential administration's policy proposals), revisions to reimbursement of biopharmaceuticals under government programs (such as the implementation of international reference pricing for medicare part b drugs, or changes to protected class criteria for part d drugs), restrictions on u.s. direct-to-consumer advertising, limitations on interactions with healthcare professionals, or the use of comparative effectiveness methodologies that could be implemented in a manner that focuses primarily on cost differences and minimizes the therapeutic differences among pharmaceutical products and restricts access to innovative medicines.
pfizer inc.   2019 form 10-k table of contents u.s. entitlement reform in the u.s., government action to reduce federal spending on entitlement programs including medicare and medicaid may affect payment for our products or services provided using our products. the congressional budget office routinely releases options for reducing federal spending, and the december 2018 release includes proposals to cap federal medicaid payments to the states, and to require manufacturers to pay a minimum rebate on drugs covered under medicare part d for low-income beneficiaries. significant medicare reductions could also result if, for example, congress proceeds with certain proposals to convert the medicare fee-for-service program into a premium support program, or congress chooses to implement the recommendations made annually by the medicare payment advisory commission, which are primarily intended to extend the fiscal solvency of the medicare program. these and any other significant spending reductions or cost controls affecting medicare, medicaid or other publicly funded or subsidized health programs that may be implemented could have an adverse impact on our results of operations.
substantial regulation we are subject to extensive, complex, costly and evolving regulation by federal and state governmental authorities in the u.s., principally by the fda and the dea, and foreign regulatory authorities. failure to comply with all applicable regulatory requirements may subject us to operating restrictions and criminal prosecution, monetary penalties and other disciplinary actions, including, sanctions, warning letters, product seizures, recalls, fines, injunctions, suspension, revocation of approvals, corporate integrity or deferred prosecution agreements or exclusion from future participation in government healthcare programs, as well as reputational harm.
development, regulatory approval and marketing of products innovation is critical to the success of our company, and drug discovery and development are time-consuming, expensive and unpredictable. the outcome of the lengthy and complex process of identifying new compounds and developing new products is inherently uncertain and involves a high degree of risk and cost. the process from early discovery to design and adequate implementation of clinical trials to regulatory approval can take many years. drug candidates can and do fail at any stage of the process, including as the result of unfavorable pre-clinical and clinical trial results, or unfavorable new clinical data and further analyses of existing clinical data, including results that may not support further clinical development of the applicable product candidate or indication. we may not be able to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates. similarly, we may not be able to successfully address all of the comments received from regulatory authorities such as the fda and the ema, or obtain approval from regulators. regulatory approval of drug or biologic products depends on myriad factors, including a regulator making a determination as to whether a product's benefits outweigh its known risks and a determination of the product's efficacy. additionally, clinical trial data are subject to differing interpretations and assessments by regulatory authorities. even after a drug or biologic is approved, it could be adversely affected by regulatory decisions impacting labeling, manufacturing processes, safety and/or other matters. we may not be able to receive or maintain favorable recommendations by technical or advisory committees, such as the advisory committee on immunization practices that may impact the use of our vaccines. further, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates can result in a negative impact on product sales, product recalls or withdrawals, and/or consumer fraud, product liability and other litigation and claims. increasing regulatory scrutiny of drug safety and efficacy, with regulatory authorities increasingly focused on product safety and the risk/benefit profile of products as they relate to already-approved products, has resulted in a more challenging, expensive and lengthy regulatory approval process due to requests for, among other things, additional or more extensive clinical trials prior to granting approval or increased post-approval requirements. for these and other reasons discussed in item 1a. risk factors, we may not obtain the approvals we expect within the timeframe we anticipate, or at all.
post-approval data as a condition to granting marketing approval of a product, the fda may require a company to conduct additional clinical trials. the results generated in these phase 4 trials could result in the loss of marketing approval, changes in product labeling, and/or new or increased concerns about the side effects or efficacy of a product. regulatory agencies in countries outside the u.s. often have similar authority and may impose comparable requirements. for example, in july and december 2019, the fda updated the u.s. prescribing information for xeljanz to include three additional boxed warnings as well as changes to the indication and dosing for ulcerative colitis. in january 2020, the ema revised the summary of product characteristics (smpc) for xeljanz to include new warnings and recommendations for use of xeljanz due to an increased risk of venous thromboembolism and, due to an increased risk of infections, revised warnings in patients older than 65 years of age. these updates were based on the fda's and ema's review of data from the ongoing post-marketing requirement rheumatoid arthritis study a3921133. postmarketing studies, whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other emerging data about marketed products, such as adverse event reports, may also adversely affect the availability or commercial potential of our products. further, the discovery of significant problems with a product similar to one of our products could implicate the entire class of products; and this, in turn, could have an adverse effect on the availability or commercial viability of our product(s) as well as other products in the class.
pfizer inc.   2019 form 10-k table of contents interactions with healthcare professionals and government officials risks and uncertainties apply if we provide, offer, or promise something of value to a healthcare professional, other healthcare provider and/or government official. requirements or industry standards in the u.s. and certain jurisdictions abroad that require pharmaceutical manufacturers to track and disclose financial interactions with healthcare professionals and healthcare providers increase government and public scrutiny of such financial interactions. if an interaction is found to be improper, government enforcement actions and penalties could result. these risks may increase as both u.s. and foreign enforcement agencies adopt or increase enforcement efforts in respect of existing and new laws and regulations governing product promotion, marketing, anti-bribery and kickbacks, industry regulations, and codes of conduct.
changes in laws and accounting standards our future results could be adversely affected by changes in interpretations of existing laws and regulations, or changes in laws and regulations, including, among others, changes in accounting standards, taxation requirements (including tax rate changes, new tax laws, changes to existing tax laws and revised tax law and regulatory clarifications and/or interpretations, including changes affecting the taxation by the u.s. of income earned outside the u.s. that may result from pending and possible future proposals, including further clarifications and/or interpretations of or changes to the u.s. tax cuts and jobs act of 2017), competition laws, privacy laws and environmental laws in the u.s. and other countries. for additional information, see the provision/(benefit) for taxes on income-changes in tax laws and new accounting standards sections, and the notes to consolidated financial statements-note 1b. basis of presentation and significant accounting policies: adoption of new accounting standards in 2019 in our 2019 financial report.
legal proceedings we and certain of our subsidiaries are involved in various legal proceedings, including patent litigation, such as claims that our patents are invalid and/or do not cover the product of the generic drug manufacturer or where one or more third parties seeks damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities, product liability and other product-related litigation, including personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, commercial, environmental, government investigations, employment, tax litigation and other legal proceedings, including various means for resolving asbestos litigation, that arise from time to time in the ordinary course of our business. litigation is inherently unpredictable, and excessive verdicts do occur. although we believe that our claims and defenses in matters in which we are a defendant are substantial, we could in the future incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid.
claims against our patents include challenges to the coverage and/or validity of our patents on various products or processes. although we believe we have substantial defenses to these challenges with respect to all of our material patents, there can be no assurance as to the outcome of these matters, and a loss in any of these cases could result in a loss of patent protection for the product at issue, which could lead to a significant loss of sales of that product and could materially affect future results of operations.
like other pharmaceutical companies, we are subject to extensive regulation by government agencies in the u.s., other developed markets and multiple emerging markets in which we operate. criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the u.s. and other jurisdictions in which we do business. in addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government.
our activities relating to the sale and marketing and the pricing of our products are subject to extensive regulation under the ffdca, the medicaid drug rebate program, the fcpa and other federal and state statutes, including those discussed elsewhere in this 2019 form 10-k, as well as anti-kickback and false claims laws, and similar laws in international jurisdictions. like many companies in our industry, we have from time to time received inquiries and subpoenas and other types of information demands from government authorities, and been subject to claims and other actions related to our business activities brought by governmental authorities, as well as by consumers and private payers. in some instances, we have incurred significant expense, civil payments, fines and other adverse consequences as a result of these claims, actions and inquiries. for example, these claims, actions and inquiries may relate to alleged failures to accurately interpret or identify or prevent non-compliance with the laws and regulations associated with the dissemination of product information (approved and unapproved), potentially resulting in government enforcement and damage to our reputation. this risk may be heightened by digital marketing, including social media, mobile applications and blogger outreach.
in connection with the resolution of a u.s. government investigation concerning independent copay assistance organizations that provide financial assistance to medicare patients, in may 2018, we entered into a corporate integrity agreement (cia) with the office of the inspector general of the u.s. department of health and human services, which is effective for a period of five pfizer inc.   2019 form 10-k table of contents years. in the cia, we agreed to implement and/or maintain certain compliance program elements to promote compliance with federal healthcare program requirements. breaches of the cia could result in severe sanctions against us.
for additional information, including information regarding certain legal proceedings in which we are involved in, see the notes to consolidated financial statements-note 16a. contingencies and certain commitments-legal proceedings in our 2019 financial report.
environmental claims and proceedings we and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business relating to environmental claims and proceedings. amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. while we have accrued for worldwide environmental liabilities, there is no guarantee that additional costs will not be incurred beyond the amounts accrued. if we fail to properly manage the safety of our facilities and the environmental risks associated therewith or if we are required to increase our accruals for contingencies for environmental claims and proceedings in the future, it could potentially have an adverse effect on our results of operations.
patent protection our long-term success largely depends on our ability to market technologically competitive products. we rely and expect to continue to rely on a combination of intellectual property, including patent, trademark, trade dress, copyright, trade secret and domain name protection laws, as well as confidentiality and license agreements, to protect our intellectual property and proprietary rights. if we fail to obtain and maintain adequate intellectual property protection, we may not be able to prevent third parties from launching generic or biosimilar versions of our branded products, using our proprietary technologies or from marketing products that are very similar or identical to ours. our currently pending or future patent applications may not result in issued patents, or be granted on a timely basis. similarly, any term extensions that we seek may not be granted on a timely basis, if at all. in addition, our issued patents may not contain claims sufficiently broad to protect us against third parties with similar technologies or products or provide us with any competitive advantage, including exclusivity in a particular product area. the scope of our patent claims also may vary between countries, as individual countries have distinct patent laws. we may be subject to challenges by third parties regarding our intellectual property, including, among others, claims regarding validity, enforceability, scope and effective term.
our ability to enforce our patents also depends on the laws of individual countries and each country's practice with respect to enforcement of intellectual property rights, and the extent to which certain sovereigns may seek to engage in policies or practices that may weaken its intellectual property framework (e.g., laws or regulations that promote or provide broad discretion to issue a compulsory license). in countries that provide some form of regulatory exclusivity, mechanisms exist permitting some form of challenge to our patents by competitors or generic drug marketers prior to or immediately following the expiration of such regulatory exclusivity, and generic companies are increasingly employing aggressive strategies, such as "at risk" launches that challenge our patent rights. most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. independent actions have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. such claims may also be brought as counterclaims to actions we bring to enforce our patents. we are also party to other patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for alleged delay of generic entry. we also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the u.s. patent and trademark office, the european patent office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. also, if one of our patents is found to be invalid in such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. for example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the u.s. in october 2017, the patent trial and appeal board (ptab) refused to initiate proceedings as to two patents. in june 2018, the ptab ruled on another patent, holding that one claim was valid and that all other claims were invalid. the party challenging that patent has appealed the decision. in november 2019, the federal circuit vacated the ptab's ruling and requested that the ptab redecide the challenge. in march and june 2019, an additional patent was found invalid in separate proceedings by the ptab. we have appealed. challenges to other patents remain pending in jurisdictions outside the u.s. the invalidation of all of these patents in our pneumococcal portfolio could potentially allow a competitor pneumococcal vaccine into the marketplace. further, if we are unable to maintain our existing license agreements or other agreements pursuant to which third parties grant us rights to intellectual property, including because such agreements expire or are terminated, our operating results and financial condition could be materially adversely affected.
likewise, in the u.s. and other countries, we currently hold issued trademark registrations and have trademark applications pending, any of which may be the subject of a governmental or third-party objection, which could prevent the maintenance or issuance of the trademark. as our products mature, our reliance on our trademarks and trade dress to differentiate us from our competitors increases and as a result, if we are unable to prevent third parties from adopting, registering or using trademarks pfizer inc.   2019 form 10-k table of contents and trade dress that infringe, dilute or otherwise violate our trademark rights, our business could be materially adversely affected. we actively seek to protect our proprietary information, including our trade secrets and proprietary know-how, by requiring our employees, consultants, other advisors and other third parties to execute proprietary information and confidentiality agreements upon the commencement of their employment, engagement or other relationship. despite these efforts and precautions, we may be unable to prevent a third party from copying or otherwise obtaining and using our trade secrets or our other intellectual property without authorization, and legal remedies in some countries may not adequately compensate us for the damages caused by such unauthorized use. further, others may independently and lawfully develop substantially similar or identical products that circumvent our intellectual property by means of alternative designs or processes or otherwise.
third party intellectual property claims a properly functioning intellectual property regime is essential to our business model. we are committed to respecting the valid intellectual property rights of other companies, but the patent granting process is imperfect. accordingly, the pursuit of valid business opportunities may require us to challenge intellectual property rights held by other companies that we believe were improperly granted. such challenges may include negotiation and litigation, which may not always be successful.
part of our business depends upon successfully identifying generic pharmaceutical product and biosimilar opportunities and launching products to take advantage of those opportunities, which may involve litigation, associated costs and time delays, and may ultimately not be successful. these opportunities may arise in situations where patent protection of equivalent branded products has expired, where patents have been declared invalid, or where products do not infringe the patents of others, and in some circumstances we may take action, such as litigation, asserting that our products do not infringe patents of existing products or that those patents are invalid or unenforceable in order to achieve a "first-to-market" or early market position for our products.
third parties may claim that our products infringe one or more patents owned or controlled by the third party. claims of intellectual property infringement can be costly and time-consuming to resolve, may delay or prevent product launches, and may result in significant damages. we are involved in patent-related disputes with third parties over our attempts to market generic pharmaceutical products and biosimilars. once we have final regulatory approval of the related generic pharmaceuticals products or biosimilars, we may decide to commercially market these products even though associated legal proceedings (including any appeals) have not been resolved (i.e., "at-risk" launch). if one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like hospira, is found to have willfully infringed valid patent rights of a third party. any of these adverse consequences could have a material adverse effect on our profitability and financial condition.
risk related to technology:
information technology and security significant disruptions of information technology systems or breaches of information security could adversely affect our businesses. we rely to a large extent upon sophisticated information technology systems to operate our businesses. in the ordinary course of business, we collect, store and transmit large amounts of confidential information (including, but not limited to, personal information and intellectual property), and we deploy and operate an array of technical and procedural controls to maintain the confidentiality and integrity of such confidential information. we also have outsourced significant elements of our operations to third parties, including significant elements of our information technology infrastructure and, as a result, we are managing many independent vendor relationships with third parties who may or could have access to our confidential information. the size and complexity of our information technology and information security systems, and those of our third-party vendors with whom we contract (and the large amounts of confidential information that is present on them), make such systems potentially vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees or vendors, or from attacks by malicious third parties. such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives (including, but not limited to, industrial espionage) and expertise, including organized criminal groups, "hacktivists," nation states and others. as a global pharmaceutical company, our systems are subject to frequent attacks. due to the nature of some of these attacks, there is a risk that they may remain undetected for a period of time. while we have invested in the protection of data and information technology, our efforts may not prevent service interruptions or security breaches. any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us. we maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems.
pfizer inc.   2019 form 10-k table of contents risks related to our strategic transactions:
strategic acquisitions the success of any of our strategic acquisitions will depend, in large part, on our ability to realize anticipated benefits from combining these businesses with pfizer. we, for example, may fail to achieve cost savings anticipated with certain of these acquisitions, or such cost savings within the expected time frame. similarly, the accretive impact anticipated from certain of these acquisitions may not be realized or may be delayed. integration of these businesses may result in the loss of key employees, the disruption of ongoing business, including third-party relationships, or inconsistencies in standards, controls, procedures and policies. we also may fail to generate the revenue growth for the acquired business that we expected at the time of entering into the transaction. expected revenue from acquired products and product candidates also may be constrained by developments outside of our control. unsuccessful clinical trials, regulatory hurdles and commercialization challenges may adversely impact revenue and income contribution from products and product candidates, including those acquired in these acquisitions. hospira, for example, has experienced manufacturing disruptions and substantial regulatory scrutiny due to quality issues. manufacturing problems, as well as any corrective actions and their operational implementation, could adversely impact the revenue we generate from products acquired from hospira and result in substantial unanticipated costs. for additional information, see the overview of our performance, operating environment, strategy and outlook--our business development initiatives section in our 2019 financial report.
pending combination of upjohn with mylan pfizer, mylan and upjohn may be unable to satisfy the conditions or obtain the approvals required to complete the combination of upjohn with mylan (the combination), and regulatory agencies may delay or impose conditions on approval of the combination, which may diminish the anticipated benefits of the combination.
the consummation of the combination is subject to numerous conditions, including the receipt by pfizer of an internal revenue service ruling and an opinion of its tax counsel to the effect that, among other things, certain transactions related to the combination and certain related transactions will constitute a tax-free "reorganization" within the meaning of section 368(a)(1)(d) of the internal revenue code, the approval of the combination by mylan shareholders, and other customary conditions, certain of which are dependent upon the actions of third parties. as a result of such conditions, pfizer cannot make any assurances that the combination will be consummated on the terms or timeline currently contemplated, or at all.
completion of the combination is also conditioned upon the receipt of certain required government consents and approvals, including certain approvals required from regulatory agencies. while pfizer, mylan and upjohn intend to pursue vigorously all required governmental approvals, the requirement to receive these approvals prior to the consummation of the combination could delay the completion of the combination, possibly for a significant period of time. any delay in the completion of the combination could diminish the anticipated benefits of the combination or result in additional transaction costs, loss of revenue or other effects associated with uncertainty about the combination, including delaying pfizer's ability to capitalize on its strategy of becoming a more focused, innovative company as well as upjohn's ability to optimize the execution of its growth strategies.
pfizer may be subject to shareholder lawsuit, or other actions filed in connection with or in opposition to the combination or any related transactions. such litigation could have an adverse effect on the business, financial condition and results of operations of pfizer and could prevent or delay the consummation of the combination.
pfizer has expended and will continue to expend significant management time and resources and has incurred and will continue to incur significant expenses due to legal, advisory, printing and financial services fees related to the combination, including costs required to obtain the required government consents or defend or settle actions noted above. we expect to incur costs of approximately $500 million in connection with fully separating upjohn, inclusive of $145 million incurred in 2019. such charges will include costs and expenses related to separation of legal entities and anticipated transaction costs. many of these expenses must be paid regardless of whether the combination is consummated, and even if the expected benefits of the combination are not achieved. additionally, the completion of the combination, including for example, obtaining regulatory approvals, will require significant time and attention from pfizer management and may divert attention from the day-to-day operations of our business.
even if the combination is completed as anticipated, pfizer may not realize some or all of the expected benefits. furthermore, upjohn may experience operational challenges in integrating the upjohn and mylan businesses, which may also diminish the anticipated benefits of the combination.
even if the combination is completed, the anticipated operational, financial, strategic and other benefits of the combination may not be achieved. there are many factors that could impact the anticipated benefits from the combination, including, among others, strategic adjustments required to reflect the nature of our business following the combination, any negative reaction to the combination by our customers and business partners, and increased risks resulting from pfizer becoming a company that is more focused on innovative medicines. in addition, pfizer has agreed to provide certain transition services to the combined company, generally for an initial period of 24 months following the completion of the combination (with certain possibilities for extension). these obligations under the transition agreements may result in additional expenses and may divert pfizer inc.   2019 form 10-k table of contents pfizer's focus and resources that would otherwise be invested into maintaining or growing pfizer's business. an inability to realize the full extent of the anticipated benefits of the combination, as well as any delays encountered in the process, could have an adverse effect on the revenues, level of expenses and operating results of our business.
furthermore, the combination is a complex, costly and time-consuming process. even if upjohn and mylan successfully integrate, pfizer, upjohn and mylan cannot predict with certainty if or when the anticipated synergies, growth opportunities and benefits resulting from the combination will occur, or the extent to which they actually will be achieved. for example, the benefits from the combination may be offset by costs incurred in integrating the companies or by required capital expenditures related to the combined businesses. in addition, the quantification of synergies expected to result from the combination is based on significant estimates and assumptions that are subjective in nature and inherently uncertain. realization of any benefits and synergies could be affected by a number of factors beyond pfizer's, mylan's, upjohn's or the combined company's control, including, without limitation, general economic conditions, increased operating costs, regulatory developments and the other risks described in these risk factors. the amount of synergies actually realized in the combination, if any, and the time periods in which any such synergies are realized, could differ materially from the synergies anticipated to be realized, regardless of whether the two business operations are combined successfully. if the integration is unsuccessful or if the combined company is unable to realize the anticipated synergies and other benefits of the combination, there could be a material adverse effect on the combined company's share price, business, financial condition and results of operations.
consumer healthcare joint venture with gsk on july 31, 2019, we completed the transaction in which we and gsk combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the gsk consumer healthcare name. following the integration of the combined business, gsk intends to separate the joint venture as an independent company via a demerger of its equity interest to its shareholders and a listing of the combined business on the u.k. equity market. in february 2020, gsk announced the initiation of a two-year program to prepare for the separation of gsk into two companies, including a standalone consumer healthcare company. until the fifth anniversary of the closing of the transaction, gsk will have the sole right to decide whether and when to initiate a separation and listing, and may also sell all or part of its stake in the joint venture in a contemporaneous initial public offering. should a separation and listing occur during the first five years after closing, pfizer has the option to participate through the distribution of some or all of its equity interest in the joint venture to its shareholders. following a separation or listing, and subject to customary lock-up or similar restrictions, pfizer will also have the ability to sell its equity interest in the joint venture through the capital markets. after the fifth anniversary of the closing of the transaction, both gsk and pfizer will have the right to decide whether and when to initiate a separation and public listing of the joint venture. the planned separation and public listing transactions may not be initiated or completed within the expected time periods or at all, and both the timing and success of any separation and public listing transaction, as well as the value generated for pfizer or its shareholders in any such transaction, will be subject to prevailing market conditions and other factors at the time of such transaction. although pfizer is entitled to participate in any separation and listing transaction initiated by gsk prior to the fifth anniversary of the closing, it is not required to do so, and any future distribution or sale of pfizer's equity stake in the joint venture will similarly be subject to prevailing market conditions and other factors at the time of such transaction. pfizer's ability to complete any such future distribution or sale may also be impacted by the size of pfizer's retained equity stake at the time. the uncertainty relating to the separation and public listing transactions, their implementation, their timing and their yet to be determined effects on the joint venture's business may subject us and the joint venture to risks and uncertainties that may adversely affect our business and financial results.
moreover, although we have certain consent, board representation and other governance rights with respect to the joint venture, pfizer is a minority owner of the joint venture. as a result, pfizer does not have control over the joint venture, its management or its policies and we may have business interests, strategies and goals that differ in certain respects from those of gsk or the joint venture.
in addition, the joint venture will be subject to the risks associated with the joint venture's consumer healthcare business, and the business, financial condition and results of operations of the joint venture may be affected by factors that are different from or in addition to those that previously affected the business, financial condition and results of operations of pfizer's historical consumer healthcare business. many of these factors are outside of our and the joint venture's control, and could materially impact the business, financial condition and results of operations of the joint venture.
the success of the transaction will also depend, in part, on the joint venture's ability to realize the anticipated benefits and cost synergies from the transaction. these anticipated benefits and cost savings may not be realized or may not be realized within the expected time period. the joint venture's integration of pfizer's and gsk's historic consumer healthcare businesses may result in material unanticipated problems, costs, expenses, liabilities, competitive responses, and loss of customer and other business relationships. any material unanticipated issues arising from the integration process could negatively impact our stock price and our or the joint venture's future business and financial results.
pfizer inc.   2019 form 10-k table of contents other risks:
the global economic environment like all businesses of our size, we are exposed to both global and industry-specific economic conditions. governments, corporations, and insurance companies, which provide insurance benefits to patients, have implemented increases in cost-sharing and restrictions on access to medicines, potentially causing patients to switch to generic or biosimilar products, delay treatments, skip doses or use less effective treatments. as discussed above, government financing pressures can lead to negative pricing pressure in various markets where governments take an active role in setting prices, access criteria (e.g., through public or private health technology assessments), or other means of cost control.
the global economic environment has not had, nor do we anticipate that it will have, a material impact on our liquidity or capital resources. due to our significant operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future. we monitor our liquidity position continuously in the face of evolving economic conditions, but there can be no guarantee that changes in global financial markets and global economic conditions will not affect our liquidity or capital resources or impact our ability to obtain financing in the future.
we continue to monitor credit, capital restrictions and economic situations in volatile regions and markets, especially where the ability to obtain u.s. dollars for local currency is unpredictable and challenging. we cannot predict the likelihood of future changes in these economic conditions, or what impact they may have on our results of operations, financial condition or business.
in addition, given that a significant portion of our business is conducted in the eu, including the u.k., the formal change in the relationship between the u.k. and the eu caused by brexit may pose certain implications for our research, commercial and general business operations in the u.k. and the eu, including the approval and supply of our products. details on how brexit will be finally executed and the impact on the remaining eu countries will dictate how and whether the broader eu will be impacted and what the resulting impact on our business may be. for additional information, see the overview of our performance, operating environment, strategy and outlook--the global economic environment section in our 2019 financial report.
public health epidemics or outbreaks could adversely impact our business. in december 2019, a novel strain of coronavirus (covid-19) emerged in wuhan, hubei province, china. while initially the outbreak was largely concentrated in china and caused significant disruptions to its economy, it has now spread to several other countries and infections have been reported globally. the extent to which the coronavirus impacts our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. in particular, the continued spread of the coronavirus globally could adversely impact our operations, including among others, our manufacturing and supply chain, sales and marketing and clinical trial operations and could have an adverse impact on our business and our financial results.
we also continue to monitor the global trade environment and potential trade conflicts and impediments. if trade restrictions or tariffs reduce global economic activity, or if other factors lead to a general economic downturn, potential impacts could include declining sales; increased costs; volatility in foreign exchange rates; a decline in the value of our financial assets and pension plan investments; required increases of our pension funding obligations; increased government cost control efforts; delays or failures in the performance of customers, suppliers, and other third parties on whom we may depend for the performance of our business; and the risk that our allowance for doubtful accounts may not be adequate.
foreign exchange and interest rate risk significant portions of our revenues, costs and expenses, as well as our substantial international net assets, are exposed to changes in foreign exchange rates. 54% of our total 2019 revenues were derived from international operations, including 21% from europe and 24% from china, japan and the rest of asia. as we operate in multiple foreign currencies, including the euro, the chinese renminbi, the japanese yen, the canadian dollar, the u.k. pound and approximately 100 other currencies, changes in those currencies relative to the u.s. dollar will impact our revenues and expenses. if the u.s. dollar were to weaken against another currency, assuming all other variables remained constant, our revenues would increase, having a positive impact on earnings, and our overall expenses would increase, having a negative impact on earnings. conversely, if the u.s. dollar were to strengthen against another currency, assuming all other variables remained constant, our revenues would decrease, having a negative impact on earnings, and our overall expenses would decrease, having a positive impact on earnings. therefore, significant changes in foreign exchange rates can impact our results and our financial guidance.
the impact of possible currency devaluations in countries experiencing high inflation rates or significant exchange fluctuations, including venezuela and argentina, can impact our results and financial guidance. for additional information about our exposure to foreign currency risk, see the item 7a. quantitative and qualitative disclosures about market risk-foreign exchange risk section in this 2019 form 10-k and the overview of our performance, operating environment, strategy and pfizer inc.   2019 form 10-k table of contents outlook--our financial guidance for 2020 and analysis of financial condition, liquidity and capital resources sections in our 2019 financial report.
in addition, our interest-bearing investments and borrowings, and our pension benefit obligations, net, and our postretirement benefit obligations, net, are subject to risk from changes in interest rates and foreign exchange rates. these risks related to interest-bearing investments and borrowings and the measures we have taken to help contain them are discussed in the item 7a. quantitative and qualitative disclosures about market risk-financial risk management section in this 2019 form 10-k. for additional details, see the significant accounting policies and application of critical accounting estimates and assumptions--benefit plans section and the notes to consolidated financial statements-note 7f. financial instruments: derivative financial instruments and hedging activities and -note 11. pension and postretirement benefit plans and defined contribution plans in our 2019 financial report, which are incorporated by reference.
from time to time, we issue variable rate debt based on libor, or undertake interest rate swaps that contain a variable element based on libor. the u.k. financial conduct authority announced in july 2017 that it will no longer compel banks to submit rates that are currently used to calculate libor after 2021. various governing parties, including government agencies, are working on a benchmark transition plan for libor (and other interbank offered rates globally). we are monitoring their progress, and we will likely amend contracts to accommodate any replacement rate where it is not already provided. as a result, our interest expense could increase and our available cash flow for general corporate requirements may be adversely affected. additionally, uncertainty as to the nature of a potential discontinuance, modification, alternative reference rates or other reforms may materially adversely affect the trading market for securities linked to such benchmarks. for additional information, see the analysis of financial condition, liquidity and capital resources-selected measures of liquidity and capital resources-libor section in our 2019 financial report.
notwithstanding our efforts to foresee and mitigate the effects of changes in external fiscal circumstances, we cannot predict with certainty changes in currency and interest rates, inflation or other related factors affecting our businesses.
market fluctuations in our equity investments in 2018, we adopted a new accounting standard whereby certain equity investments are measured at fair value with changes in fair value now recognized in net income. we expect the adoption of this new accounting standard may increase the volatility of our income in future periods due to changes in the fair value of certain equity investments. for additional information, see the notes to consolidated financial statements-note 4. other (income)/deductions-net in our 2019 financial report and the item 7a. quantitative and qualitative disclosures about market risk-financial risk management section in this 2019 form 10-k.
our pension benefit obligations and postretirement benefit obligations, net of our plan assets, are subject to volatility from changes in fair value of equity investments and other investment risk. for additional information, see the significant accounting policies and application of critical accounting estimates and assumptions-benefit plans section and the notes to consolidated financial statements-note 11. pension and postretirement benefit plans and defined contribution plans in our 2019 financial report.
cost and expense control/unusual events/failure to realize the anticipated benefits of strategic initiatives and acquisitions growth in costs and expenses, changes in product, segment and geographic mix and the impact of acquisitions, divestitures, restructurings, internal reorganizations, product withdrawals, recalls and other unusual events that could result from evolving business strategies, evaluation of asset realization and organizational restructuring could adversely affect future results. such risks and uncertainties include, in particular, our ability to realize the projected benefits of (i) our cost-reduction and productivity initiatives; (ii) the reorganization of our commercial operations in 2019; (iii) any other corporate strategic initiatives; and (iv) any acquisitions, divestitures or other initiatives, such as our agreement to combine upjohn with mylan, creating a new global pharmaceutical company, which is anticipated to close in mid-2020, our acquisition of array and the formation of the new consumer healthcare joint venture with gsk.
intangible assets, goodwill and equity-method investments our consolidated balance sheet contains significant amounts of intangible assets, including goodwill. for ipr&d assets, the risk of failure is significant, and there can be no certainty that these assets ultimately will yield successful products. the nature of the biopharmaceutical business is high-risk and requires that we invest in a large number of projects in an effort to achieve a successful portfolio of approved products. our ability to realize value on these significant investments is often contingent upon, among other things, regulatory approvals and market acceptance. as such, we expect that many of these ipr&d assets will become impaired and be written off at some time in the future. if the associated r&d effort is abandoned, the related ipr&d assets will likely be written-off, and we will record an impairment charge. for goodwill, all reporting units can confront events and circumstances that can lead to a goodwill impairment charge (such as, among other things, unanticipated competition, an adverse action or assessment by a regulator, a significant adverse change in legal matters or in the business climate and/or a failure to replace the contributions of products that lose exclusivity). any such charge may be significant. our other intangible pfizer inc.   2019 form 10-k table of contents assets, including developed technology rights and brands, face similar risks for impairment and charges related to such assets may be significant as well. for additional details, see the significant accounting policies and application of critical accounting estimates and assumptions section in our 2019 financial report.
we also regularly review our equity-method investments for impairment. an impairment charge may result from the occurrence of unexpected adverse events or management decisions that impact our estimates of expected cash flows to be generated from these investments. we may recognize impairment charges as a result of a weak economic environment, events related to particular customers or asset types, challenging market conditions or decisions by management.
terrorist activity our future results could be adversely affected by changes in business, political and economic conditions, including the cost and availability of insurance, due to the threat of terrorist activity in the u.s. and other parts of the world and related u.s. military action overseas.
pfizer inc.   2019 form 10-k table of contents
item 7.   management's discussion and analysis of financial condition and results of operations information required by this item is incorporated by reference from the discussion under the heading financial review in our 2019 financial report.